SCHEMBL6673884

SCHEMBL6673884

Cc1ccc(-c2ccccc2C(=O)Nc2cc(C(=O)O)n(C)c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.55
CHRNB2 P17787 1/20 0.51
CHRNB4 P30926 1/20 0.51
CHRNA3 P32297 1/20 0.51
CHRNA4 P43681 1/20 0.51
LMNA P02545 1/20 0.49
HTT P42858 3/20 0.46
GAA P10253 3/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 3/20 0.46
POLB P06746 1/20 0.46
TP53 P04637 1/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
RAB9A P51151 1/20 0.45
AVPR2 P30518 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
ALOX12 P18054 1/20 0.45
AURKA O14965 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7039846 0.93 CHRNB2 (0.60) L3MBTL1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL6675658 0.89 HTT (0.54) L3MBTL1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL6278519 0.86 MTTP (0.55) CHRNB2CHRNB4CHRNA3CHRNA4LMNA
SCHEMBL7039230 0.84 CHRNB2 (0.51) L3MBTL1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL7039859 0.84 CHRNB2 (0.47) L3MBTL1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL6673887 0.83 L3MBTL1 (0.52) L3MBTL1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL31393753 0.80 CHRNB2 (0.78) L3MBTL1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL7041084 0.80 LMNA (0.46) CHRNB2CHRNB4CHRNA3CHRNA4LMNA
SCHEMBL7035898 0.78 MTTP (0.50) GAAKDM4E
SCHEMBL7372972 0.77 CHRNB2 (0.63) L3MBTL1CHRNB2CHRNB4CHRNA3CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1465613-A2 COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2004-10-13 EP disclosed
US-20030162788-A1 Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-08-28 US disclosed
WO-2003057205-A2 COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-07-17 WO disclosed
US-20030073836-A1 Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-04-17 US disclosed
WO-2003004020-A1 HETEROARYL CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS INHIBITORS OF THE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162788-A1 Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals APOB, LIPC, MTPN L3MBTL1 2563/4885CHRNB2 4509/4885CHRNB4 4364/4885
US-20030073836-A1 Heteroarylcarboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions MTTP, CETP, CES1 L3MBTL1 2996/4885CHRNB2 4806/4885CHRNB4 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.